Liofora Diario (Drospirenone, Ethinylestradiol | Lactose Monohydrate)

The drospirenone component acts as a progestin with anti‑mineralocorticoid and anti‑androgenic properties, while ethinylestradiol provides estrogenic activity. Together they suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation, and they modify cervical mucus and the endometrial lining to reduce the chance of fertilisation and implantation.

The dosing regimen for Liofora Diario is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule, duration, and any special instructions are set by the prescriber based on the individual’s clinical needs.

Liofora Diario is contraindicated during pregnancy because it is intended to prevent conception, not to support an existing pregnancy. Women who become pregnant should discontinue use immediately. Safety data for breastfeeding are limited; the decision to use the product while nursing should be made by a healthcare provider after weighing potential risks and benefits.

To order Liofora Diario, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the initial request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Liofora Diario contains drospirenone, a progestin with anti‑mineralocorticoid and anti‑androgenic activity, which may offer benefits such as reduced water retention and improved acne control compared with some older progestins. Efficacy in preventing pregnancy is comparable to other combined oral contraceptives, but the side‑effect profile and individual tolerability can differ, so clinicians choose the formulation that best matches a patient’s health status and preferences.

Liofora Diario tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture, heat and direct sunlight. Keep the medication out of reach of children and do not use it after the expiry date printed on the packaging.

Liofora Diario is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and can be taken with or without food. If a dose is missed, follow the product’s missed‑dose instructions or consult a healthcare professional for guidance on backup contraception.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis such as stroke or myocardial infarction, and severe allergic reactions. These events are rare but can be life‑threatening, especially in women with pre‑existing cardiovascular risk factors, smoking habits, or certain genetic clotting disorders.

Liofora Diario should be avoided by women who are pregnant, have a known or suspected breast cancer, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It is also contraindicated in individuals with known hypersensitivity to drospirenone, ethinylestradiol, lactose, or any other excipients in the tablet.